Psychiatric and developmental conditions in 22q11.2 deletion syndrome (22q11.2DS) are common, yet clinicians have had no reliable blood test to flag who is at risk or to track disease over time. In a study our Dalton Bioanalytics scientists co-authored with the UC Davis MIND Institute, we asked a direct question: can untargeted metabolomics and proteomics read coordinated molecular changes in plasma that single-layer tests miss? Profiling proteins and metabolites together tur